Phospholipase A2 enzymes (PLA2s) catalyze the hydrolysis of glycerophospholipids at their sn-2 position releasing free fatty acids and lysophospholipids. Mammalian PLA2s are classified into several categories of which important groups include secreted PLA2s (sPLA2s) and cytosolic PLA2s (cPLA2s) that are calcium-dependent for their catalytic activity and calcium-independent cytosolic PLA2s (iPLA2s). Platelet-activating factor acetylhydrolases (PAF-AHs), lysosomal PLA2s, and adipose-specific PLA2 also belong to the class of PLA2s. Generally, cPLA2 enzymes are believed to play a major role in the metabolism of arachidonic acid, the iPLA2 family to membrane homeostasis and energy metabolism, and the sPLA2 family to various biological processes. The focus of this review is on recent research developments in the sPLA2 field. sPLA2s are secreted enzymes with low molecular weight (with the exception of GIII sPLA2), Ca2+-requiring enzymes with a His-Asp catalytic dyad. Ten enzymatically active sPLA2s and one devoid of enzymatic activity have been identified in mammals. Some of these sPLA2s are potent in arachidonic acid release from cellular phospholipids for the biosynthesis of eicosanoids, especially during inflammation. Individual sPLA2 enzymes exhibit unique tissue and cellular localizations and specific enzymatic properties, suggesting their distinct biological roles. Recent studies indicate that sPLA2s are involved in diverse pathophysiological functions and for most part act nonredundantly. 1. Introduction Secreted phospholipases A2 (sPLA2s) are secreted from a variety of cells and act in autocrine or paracrine manners on cell membranes and other extracellular phospholipids, including lipoprotein particles, surfactant and dietary lipids, microbial membranes, and microvesicles？？[1]. Even though sPLA2s are considered to act as extracellularly requiring millimolar concentrations of Ca2+, few in vitro reports also indicate possible intracellular activity prior to or during secretion？？[2]. To date, eleven sPLA2 enzymes, group IB (GIB), group IIA (GIIA), group IIC (GIIC), group IID (GIID), group IIE (GIIE), group IIF (GIIF), group III (GIII), group V (GV), group X (GX), group XIIA (GXIIA), and group XIIB (GXIIB), have been identified in mammals [3–5]. GIII sPLA2 is an atypical sPLA2 that contains unique N-terminal and C-terminal domains and a central sPLA2 domain, the S domain, which has higher homology with bee venom sPLA2 (a prototypic group III enzyme) than with other known mammalian sPLA2s [6]. Another unique member is GXIIB protein which has structural
References
[1]
M. Murakami, Y. Taketomi, H. Sato, and K. Yamamoto, “Secreted phospholipase A2 revisited,” Journal of Biochemistry, vol. 150, no. 3, pp. 233–255, 2011.
[2]
C. M. Mounier, F. Ghomashchi, M. R. Lindsay et al., “Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A2 occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2-α,” Journal of Biological Chemistry, vol. 279, no. 24, pp. 25024–25038, 2004.
[3]
M. Murakami and I. Kudo, “Diversity and regulatory functions of mammalian secretory phospholipase A2s,” Advances in Immunology, vol. 77, pp. 163–194, 2001.
[4]
I. Kudo and M. Murakami, “Phospholipase A2 enzymes,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 3–58, 2002.
[5]
M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, “Recent progress in phospholipase A2 research: from cells to animals to humans,” Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011.
[6]
E. Valentines, F. Ghomashchi, M. H. Gelb, M. Lazdunski, and G. Lambeau, “Novel human secreted phospholipase A2 with homology to the group III bee venom enzyme,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 7492–7496, 2000.
[7]
M. Rouault, J. G. Bollinger, M. Lazdunski, M. H. Gelb, and G. Lambeau, “Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity,” Biochemistry, vol. 42, no. 39, pp. 11494–11503, 2003.
[8]
M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, “Recent progress in phospholipase A2 research: from cells to animals to humans,” Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011.
[9]
M. Murakami, Y. Taketomi, C. Girard, K. Yamamoto, and G. Lambeau, “Emerging roles of secreted phospholipase A2 enzymes: lessons from transgenic and knockout mice,” Biochimie, vol. 92, no. 6, pp. 561–582, 2010.
[10]
B. B. Boyanovsky and N. R. Webb, “Biology of secretory phospholipase A2,” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 61–72, 2009.
[11]
G. Lambeau and M. H. Gelb, “Biochemistry and physiology of mammalian secreted phospholipases A 2,” Annual Review of Biochemistry, vol. 77, pp. 495–520, 2008.
[12]
T. Matsuoka, M. Hirata, H. Tanaka et al., “Prostaglandin D2 as a mediator of allergic asthma,” Science, vol. 287, no. 5460, pp. 2013–2017, 2000.
[13]
K. Terawaki, T. Yokomizo, T. Nagase et al., “Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses,” Journal of Immunology, vol. 175, no. 7, pp. 4217–4225, 2005.
[14]
A. M. Tager, S. K. Bromley, B. D. Medoff et al., “Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment,” Nature Immunology, vol. 4, no. 10, pp. 982–990, 2003.
[15]
Z. Jaffar, M. E. Ferrini, M. C. Buford, G. A. FitzGerald, and K. Roberts, “Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma,” Journal of Immunology, vol. 179, no. 9, pp. 6193–6203, 2007.
[16]
T. Kunikata, H. Yamane, E. Segi et al., “Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3,” Nature Immunology, vol. 6, no. 5, pp. 524–531, 2005.
[17]
C. G. Irvin, Y. Tu, J. R. Sheller, and C. D. Funk, “5-lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 272, no. 6, pp. L1053–L1058, 1997.
[18]
B. D. Levy, G. T. De Sanctis, P. R. Devchand et al., “Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4,” Nature Medicine, vol. 8, no. 9, pp. 1018–1023, 2002.
[19]
O. Haworth, M. Cernadas, R. Yang, C. N. Serhan, and B. D. Levy, “Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation,” Nature Immunology, vol. 9, no. 8, pp. 873–879, 2008.
[20]
S. Offer, S. Yedgar, O. Schwob et al., “Negative feedback between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 288, no. 3, pp. L523–L529, 2005.
[21]
T. S. Hallstrand and W. R. Henderson Jr., “Role of leukotrienes in exercise-induced bronchoconstriction,” Current Allergy and Asthma Reports, vol. 9, no. 1, pp. 18–25, 2009.
[22]
E. A. Capper and L. A. Marshall, “Mammalian phospholipases A2: mediators of inflammation, proliferation and apoptosis,” Progress in Lipid Research, vol. 40, no. 3, pp. 167–197, 2001.
[23]
N. M. Mu？oz, Y. J. Kim, A. Y. Meliton et al., “Human group V phospholipase A2 induces group IVA phospholipase A2-independent cysteinyl leukotriene synthesis in human eosinophils,” The Journal of Biological Chemistry, vol. 278, no. 40, pp. 38813–38820, 2003.
[24]
N. J. Pyne, D. Tolan, and S. Pyne, “Bradykinin stimulates cAMP synthesis via mitogen-activated protein kinase-dependent regulation of cytosolic phospholipase A2 and prostaglandin E2 release in airway smooth muscle,” Biochemical Journal, vol. 328, part 2, pp. 689–694, 1997.
[25]
A. C. Sane, T. Mendenhall, and D. A. Bass, “Secretory phospholipase A2 activity is elevated in bronchoalveolar lavage fluid after ovalbumin sensitization of guinea pigs,” Journal of Leukocyte Biology, vol. 60, no. 6, pp. 704–709, 1996.
[26]
P. Vadas, “Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid,” Biochimica et Biophysica Acta, vol. 1346, no. 2, pp. 193–197, 1997.
[27]
M. Triggiani, F. Granata, A. Petraroli et al., “Inhibition of secretory phospholipase A2-induced cytokine production in human lung macrophages by budesonide,” International Archives of Allergy and Immunology, vol. 150, no. 2, pp. 144–155, 2009.
[28]
D. L. Bowton, M. C. Seeds, M. B. Fasano, B. Goldsmith, and D. A. Bass, “Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics,” The American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 2, pp. 421–425, 1997.
[29]
F. H. Chilton, F. J. Averill, W. C. Hubbard, A. N. Fonteh, M. Triggiani, and M. C. Liu, “Antigen-induced generation of lyso-phospholipids in human airways,” Journal of Experimental Medicine, vol. 183, no. 5, pp. 2235–2245, 1996.
[30]
J. M. Stadel, K. Hoyle, R. M. Naclerio, A. Roshak, and F. H. Chilton, “Characterization of phospholipase A2 from human nasal lavage.,” American Journal of Respiratory Cell and Molecular Biology, vol. 11, no. 1, pp. 108–113, 1994.
[31]
T. S. Hallstrand, Y. Lai, Z. Ni et al., “Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity,” Clinical and Experimental Allergy, vol. 41, no. 6, pp. 801–810, 2011.
[32]
A. G. Singer, F. Ghomashchi, C. Le Calvez et al., “Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2,” Journal of Biological Chemistry, vol. 277, no. 50, pp. 48535–48549, 2002.
[33]
W. R. Henderson Jr., E. Y. Chi, J. G. Bollinger et al., “Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model,” The Journal of Experimental Medicine, vol. 204, no. 4, pp. 865–877, 2007.
[34]
T. S. Hallstrand, E. Y. Chi, A. G. Singer, M. H. Gelb, and W. R. Henderson Jr., “Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness,” The American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1072–1078, 2007.
[35]
Y. Lai, R. C. Oslund, J. G. Bollinger et al., “Eosinophil cysteinyl leukotriene synthesis mediated by exogenous secreted phospholipase A2 group X,” Journal of Biological Chemistry, vol. 285, no. 53, pp. 41491–41500, 2010.
[36]
T. S. Hallstrand, Y. Lai, W. A. Altemeier et al., “Regulation and function of epithelial secreted phospholipase A2 group X in asthma,” The American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 1, pp. 42–50, 2013.
[37]
W. R. Henderson Jr., R. C. Oslund, J. G. Bollinger et al., “Blockade of human group X secreted phospholipase A 2 (GX-sPLA 2)-induced airway inflammation and hyperresponsiveness in a mouse asthma model by a selective GX-sPLA 2 inhibitor,” Journal of Biological Chemistry, vol. 286, no. 32, pp. 28049–28055, 2011.
[38]
N. Degousee, D. J. Kelvin, G. Geisslinger et al., “Group V phospholipase A2 in bone marrow-derived myeloid cells and bronchial epithelial cells promotes bacterial clearance after Escherichia coli pneumonia,” The Journal of Biological Chemistry, vol. 286, no. 41, pp. 35650–35662, 2011.
[39]
N. M. Mu？oz, A. Y. Meliton, J. P. Arm, J. V. Bonventre, W. Cho, and A. R. Leff, “Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice,” Journal of Immunology, vol. 179, no. 7, pp. 4800–4807, 2007.
[40]
G. Giannattasio, D. Fujioka, W. Xing, H. R. Katz, J. A. Boyce, and B. Balestrieri, “Group v secretory phospholipase A2 reveals its role in house dust mite-induced allergic pulmonary inflammation by regulation of dendritic cell function,” Journal of Immunology, vol. 185, no. 7, pp. 4430–4438, 2010.
[41]
B. Balestrieri, A. Maekawa, W. Xing, M. H. Gelb, H. R. Katz, and J. P. Arm, “Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans,” Journal of Immunology, vol. 182, no. 8, pp. 4891–4898, 2009.
[42]
S. Lapointe, A. Brkovic, I. Cloutier, J. Tanguay, J. P. Arm, and M. G. Sirois, “Group V secreted phospholipase A2 contributes to LPS-induced leukocyte recruitment,” Journal of Cellular Physiology, vol. 224, no. 1, pp. 127–134, 2010.
[43]
M. Ohtsuki, Y. Taketomi, S. Arata et al., “Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction,” Journal of Biological Chemistry, vol. 281, no. 47, pp. 36420–36433, 2006.
[44]
A. A. Kelvin, N. Degousee, D. Banner, et al., “Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection,” Virology, vol. 454-455, pp. 78–92, 2014.
[45]
A. Enomoto, M. Murakami, E. Valentin, G. Lambeau, M. H. Gelb, and I. Kudo, “Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells,” The Journal of Immunology, vol. 165, no. 7, pp. 4007–4014, 2000.
[46]
M. A. Balboa, J. Balsinde, M. V. Winstead, J. A. Tischfield, and E. A. Dennis, “Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages,” Journal of Biological Chemistry, vol. 271, no. 50, pp. 32381–32384, 1996.
[47]
S. Masuda, M. Murakami, M. Mitsuishi et al., “Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells,” Biochemical Journal, vol. 387, no. 1, pp. 27–38, 2005.
[48]
K. Hamaguchi, H. Kuwata, K. Yoshihara et al., “Induction of distinct sets of secretory phospholipase A2 in rodents during inflammation,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1635, no. 1, pp. 37–47, 2003.
[49]
E. Movert, Y. Wu, G. Lambeau, F. Kahn, L. Touqui, and T. Areschoug, “Secreted group iia phospholipase a2 protects humans against the group b streptococcus: experimental and clinical evidence,” The Journal of Infectious Diseases, vol. 208, pp. 2025–2035, 2013.
[50]
A. Piris-Gimenez, M. Paya, G. Lambeau et al., “In vivo protective role of human group IIA phospholipase A2 against experimental anthrax,” The Journal of Immunology, vol. 175, no. 10, pp. 6786–6791, 2005.
[51]
F. Granata, A. Frattini, S. Loffredo et al., “Signaling events involved in cytokine and chemokine production induced by secretory phospholipase A2 in human lung macrophages,” European Journal of Immunology, vol. 36, no. 7, pp. 1938–1950, 2006.
[52]
B. Balestrieri and J. P. Arm, “Group V sPLA2: classical and novel functions,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1761, no. 11, pp. 1280–1288, 2006.
[53]
M. Mitsuishi, S. Masuda, I. Kudo, and M. Murakami, “Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells,” Biochemical Journal, vol. 393, no. 1, pp. 97–106, 2006.
[54]
M. Kimura-Matsumoto, Y. Ishikawa, K. Komiyama et al., “Expression of secretory phospholipase A2s in human atherosclerosis development,” Atherosclerosis, vol. 196, no. 1, pp. 81–91, 2008.
[55]
K. Hanasaki, K. Yamada, S. Yamamoto et al., “Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation,” Journal of Biological Chemistry, vol. 277, no. 32, pp. 29116–29124, 2002.
[56]
S. A. I. Ghesquiere, M. J. J. Gijbels, M. Anthonsen et al., “Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition,” Journal of Lipid Research, vol. 46, no. 2, pp. 201–210, 2005.
[57]
S. A. Karabina, I. Brochériou, G. le Naour et al., “Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.,” The FASEB Journal, vol. 20, no. 14, pp. 2547–2549, 2006.
[58]
A. J？nsson-Rylander, S. Lundin, B. Rosengren, C. Pettersson, and E. Hurt-Camejo, “Role of secretory phospholipases in atherogenesis,” Current Atherosclerosis Reports, vol. 10, no. 3, pp. 252–259, 2008.
[59]
B. Boyanovsky, M. Zack, K. Forrest, and N. R. Webb, “The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 532–538, 2009.
[60]
H. Sato, R. Kato, Y. Isogai, et al., “Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis,” The Journal of Biological Chemistry, vol. 283, no. 48, pp. 33483–33497, 2008.
[61]
M. A. Bostrom, B. B. Boyanovsky, C. T. Jordan et al., “Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 600–606, 2007.
[62]
F. C. De Beer and N. R. Webb, “Inflammation and atherosclerosis: group iia and group v spla2 are not redundant,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1421–1422, 2006.
[63]
B. B. Boyanovsky, D. R. van der Westhuyzen, and N. R. Webb, “Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans,” Journal of Biological Chemistry, vol. 280, no. 38, pp. 32746–32752, 2005.
[64]
M. Romano, E. Romano, S. Bj？rkerud, and E. Hurt-Camejo, “Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 4, pp. 519–525, 1998.
[65]
P. Sartipy, G. Camejo, L. Svensson, and E. Hurt-Camejo, “Phospholipase A2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans,” The Journal of Biological Chemistry, vol. 274, no. 36, pp. 25913–25920, 1999.
[66]
K. Kugiyama, Y. Ota, K. Takazoe et al., “Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease,” Circulation, vol. 100, no. 12, pp. 1280–1284, 1999.
[67]
B. P. Kennedy, P. Payette, J. Mudgett et al., “A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains,” The Journal of Biological Chemistry, vol. 270, no. 38, pp. 22378–22385, 1995.
[68]
B. Ivandic, L. W. Castellani, X. Wang et al., “Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1284–1290, 1999.
[69]
U. J. F. Tietge, C. Maugeais, W. Cain et al., “Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I,” Journal of Biological Chemistry, vol. 275, no. 14, pp. 10077–10084, 2000.
[70]
F. C. de Beer, P. M. Connell, J. Yu, M. C. de Beer, N. R. Webb, and D. R. van der Westhuyzen, “HDL modification by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism,” Journal of Lipid Research, vol. 41, no. 11, pp. 1849–1857, 2000.
[71]
N. R. Webb, M. A. Bostrom, S. J. Szilvassy, D. R. van der Westhuyzen, A. Daugherty, and F. C. de Beer, “Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 263–268, 2003.
[72]
B. Rosengren, H. Peilot, M. Umaerus et al., “Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1579–1585, 2006.
[73]
L. Gesquiere, W. Cho, and P. V. Subbaiah, “Role of group IIa and group V secretory phospholipases A2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin,” Biochemistry, vol. 41, no. 15, pp. 4911–4920, 2002.
[74]
C. R. Wooton-Kee, B. B. Boyanovsky, M. S. Nasser, W. J. S. de Villiers, and N. R. Webb, “Group V spla2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 4, pp. 762–767, 2004.
[75]
B. B. Boyanovsky and N. R. Webb, “Biology of secretory phospholipase A2,” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 61–72, 2009.
[76]
B. Boyanovsky, M. Zack, K. Forrest, and N. R. Webb, “The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 532–538, 2009.
[77]
M. Zack, B. B. Boyanovsky, P. Shridas et al., “Group X secretory phospholipase A2 augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice,” Atherosclerosis, vol. 214, no. 1, pp. 58–64, 2011.
[78]
H. Ait-Oufella, O. Herbin, C. Lahoute et al., “Group X secreted phospholipase a2 limits the development of atherosclerosis in LDL receptor-null mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 3, pp. 466–473, 2013.
[79]
S. J. Nicholls, J. J. Kastelein, G. G. Schwartz et al., “Varespladib and cardiovascular events in patients with an acute coronary syndrome: the vista-16 randomized clinical trial,” The Journal of the American Medical Association, vol. 311, pp. 252–262, 2014.
[80]
T. G. Cooper, “Role of the epididymis in mediating changes in the male gamete during maturation,” Advances in Experimental Medicine and Biology, vol. 377, pp. 87–101, 1995.
[81]
J. Escoffier, I. Jemel, A. Tanemoto et al., “Group X phospholipase A2 is released during sperm acrosome reaction and controls fertility outcome in mice,” The Journal of Clinical Investigation, vol. 120, no. 5, pp. 1415–1428, 2010.
[82]
J. Escoffier, V. J. Pierre, I. Jemel et al., “Group X secreted phospholipase A2 specifically decreases sperm motility in mice,” Journal of Cellular Physiology, vol. 226, no. 10, pp. 2601–2609, 2011.
[83]
R. Abi Nahed, J. Escoffier, C. Revel et al., “The effect of group X secreted phospholipase A2 on fertilization outcome is specific and not mimicked by other secreted phospholipases A2 or progesterone,” Biochimie, vol. 99, pp. 88–95, 2014.
[84]
H. Sato, Y. Taketomi, Y. Isogai et al., “Group III secreted phospholipase A2 regulates epididymal sperm maturation and fertility in mice,” Journal of Clinical Investigation, vol. 120, no. 5, pp. 1400–1414, 2010.
[85]
G. Cavigiolio and S. Jayaraman, “Proteolysis of apolipoprotein a-i by secretory phospholipase a2: a new link between inflammation and atherosclerosis,” The Journal of Biological Chemistry, vol. 289, pp. 10011–10023, 2014.
[86]
P. Shridas, W. M. Bailey, F. Gizard et al., “Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 10, pp. 2014–2021, 2010.
[87]
A. D. Attie, J. P. Kastelein, and M. R. Hayden, “Pivotal role of ABCA1 in reverse cholesterol transport influencing HLD levels and susceptibility to atherosclerosis,” Journal of Lipid Research, vol. 42, no. 11, pp. 1717–1726, 2001.
[88]
N. Wang, D. Lan, W. Chen, F. Matsuura, and A. R. Tall, “ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9774–9779, 2004.
[89]
P. Costet, Y. Luo, N. Wang, and A. R. Tall, “Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 28240–28245, 2000.
[90]
A. Venkateswaran, B. A. Laffitte, S. B. Joseph et al., “Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR α,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12097–12102, 2000.
[91]
T. Yoshikawa, H. Shimano, N. Yahagi et al., “Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements,” Journal of Biological Chemistry, vol. 277, no. 3, pp. 1705–1711, 2002.
[92]
J. Ou, H. Tu, B. Shan et al., “Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 11, pp. 6027–6032, 2001.
[93]
P. Shridas, W. M. Bailey, F. Gizard et al., “Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 10, pp. 2014–2021, 2010.
[94]
X. Zhu, J. Lee, J. M. Timmins et al., “Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages,” Journal of Biological Chemistry, vol. 283, no. 34, pp. 22930–22941, 2008.
[95]
Y. Li, R. F. Schwabe, T. DeVries-Seimon et al., “Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-α and interleukin-6: model of NF-κB- and map kinase-dependent inflammation in advanced atherosclerosis,” Journal of Biological Chemistry, vol. 280, no. 23, pp. 21763–21772, 2005.
[96]
M. Koseki, K. Hirano, D. Masuda et al., “Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor- secretion in Abca1-deficient macrophages,” Journal of Lipid Research, vol. 48, no. 2, pp. 299–306, 2007.
[97]
L. Yvan-Charvet, C. Welch, T. A. Pagler et al., “Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions,” Circulation, vol. 118, no. 18, pp. 1837–1847, 2008.
[98]
P. Shridas, W. M. Bailey, K. R. Talbott, R. C. Oslund, M. H. Gelb, and N. R. Webb, “Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages,” Journal of Immunology, vol. 187, no. 1, pp. 482–489, 2011.
[99]
R. Sato, S. Yamaga, K. Watanabe et al., “Inhibition of secretory phospholipase A2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model,” Experimental Lung Research, vol. 36, no. 4, pp. 191–200, 2010.
[100]
P. Shridas, W. M. Bailey, B. B. Boyanovsky, R. C. Oslund, M. H. Gelb, and N. R. Webb, “Group X secretory phospholipase A2 regulates the expression of steroidogenic acute regulatory protein (StAR) in mouse adrenal glands,” Journal of Biological Chemistry, vol. 285, no. 26, pp. 20031–20039, 2010.
[101]
D. M. Stocco, “StAR protein and the regulation of steroid hormone biosynthesis,” Annual Review of Physiology, vol. 63, pp. 193–213, 2001.
[102]
A. Rigotti, E. R. Edelman, P. Seifert et al., “Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland,” Journal of Biological Chemistry, vol. 271, no. 52, pp. 33545–33549, 1996.
[103]
C. L. Cummins, D. H. Volle, Y. Zhang et al., “Liver X receptors regulate adrenal cholesterol balance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1902–1912, 2006.
[104]
K. R. Steffensen, S. Y. Neo, T. M. Stulnig et al., “Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals,” Journal of Molecular Endocrinology, vol. 33, no. 3, pp. 609–622, 2004.
[105]
L. K. Juvet, S. M. Andresen, G. U. Schuster et al., “On the role of liver X receptors in lipid accumulation in adipocytes,” Molecular Endocrinology, vol. 17, no. 2, pp. 172–182, 2003.
[106]
J. B. Seo, H. M. Moon, W. S. Kim et al., “Activated liver x receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor γexpression,” Molecular and Cellular Biology, vol. 24, no. 8, pp. 3430–3444, 2004.
[107]
X. Li, P. Shridas, K. Forrest, W. Bailey, and N. R. Webb, “Group X secretory phospholipase a2 negatively regulates adipogenesis in murine models,” FASEB Journal, vol. 24, no. 11, pp. 4313–4324, 2010.
[108]
D. Fujioka, Y. Saito, T. Kobayashi et al., “Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice,” Circulation, vol. 117, no. 23, pp. 2977–2985, 2008.
[109]
M. Guan, L. Qu, W. Tan, L. Chen, and C. Wong, “Hepatocyte nuclear factor-4 alpha regulates liver triglyceride metabolism in part through secreted phospholipase A2 GXIIB,” Hepatology, vol. 53, no. 2, pp. 458–466, 2011.
